Hypofractionated Image-Guided Radiation Therapy for Patients with Limited Volume Metastatic Non-small Cell Lung Cancer

Hasselle, Michael D.; Haraf, Daniel J.; Rusthoven, Kyle E.; Golden, Daniel W.; Salgia, Ravi; Villaflor, Victoria M.; Shah, N.; Hoffman, Philip C.; Chmura, Steven J.; Connell, Philip P.; Vokes, Everett E.; Weichselbaum, Ralph R.; Salama, Joseph K.

doi:10.1097/jto.0b013e31824166a5

Cited by 94 publications

(67 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Weichselbaum et al introduced this term to indicate that there is an intermediate state of lung cancer between metastatic and local disease. Therefore, we decided to follow the inclusion criteria of Hasselle et al and included all patients with ≤5 extrapulmonary metastases [12].…”

Section: Definition Of "Oligometastatic"mentioning

confidence: 99%

Surgical Treatment of Extrapulmonary Oligometastatic Non-small Cell Lung Cancer

et al. 2012

View full text Add to dashboard Cite

The prognosis of metastatic non-small cell lung cancer (NSCLC) is poor, and platinum-based chemotherapy improves the median survival for only a few months. A subgroup of patients with oligometastatic disease may benefit from surgical resection, but only very limited data are available to date. We conducted a retrospective review of all patients with synchronous extrapulmonary oligometastatic NSCLC undergoing surgical resection in our department. Data regarding medical history, histology, number of metastases, and survival status were extracted from the medical database

show abstract

Section: Definition Of "Oligometastatic"mentioning

confidence: 99%

Surgical Treatment of Extrapulmonary Oligometastatic Non-small Cell Lung Cancer

et al. 2012

View full text Add to dashboard Cite

show abstract

“…23,51 The relatively poor results of RT in comparison with surgery may also be attributed to differences in patient selection. 44 In the surgical literature, the majority of patients have metastases confined to the adrenal or have extra-adrenal OM which have also been aggressively treated; have usually had their primary disease resected; must be technically resectable; and medically operable.…”

Section: Discussionmentioning

confidence: 99%

“…10,23 The objective of this review was to analyze the literature describing aggressive treatment of AM (solitary or as a component of an oligometastatic presentation) secondary to NSCLC.…”

Section: Review Lung Cancermentioning

confidence: 99%

See 1 more Smart Citation

Adrenal Oligometastases Secondary to Non-small Cell Lung Cancer—What is the Optimal Treatment Approach?

Thomsen¹,

Fairchild²

2017

Oncology &Amp; Hematology Review (US)

View full text Add to dashboard Cite

B ackground: Five-year overall survival (OS) for patients with stage IV non-small cell lung cancer (NSCLC) is a dismal 1%. However, approximately 7% have limited or solitary metastases, including to the adrenal gland. Radical treatment of these oligometastases (OM) could increase local control and improve OS. Our objective was to critically analyze data describing aggressive treatment of adrenal OM secondary to NSCLC. Methods: A literature search examining English publications describing surgery or radiotherapy (RT) was performed, supplemented by searching reference lists. Case reports of three or fewer patients, and articles from which NSCLC-or adrenal-specific clinical outcomes could not be abstracted, were excluded. Results: Twenty-nine studies met eligibility criteria (521 patients), 26 retrospective. No publications directly compare modalities. Four surgery studies described contemporaneous patients treated with palliative chemotherapy (CH) alone. Reported median OS ranged from 9.5-64 months after adrenalectomy, 8-23 months after RT, and 6-8.5 months after CH. Local failure after surgery was 14%, with response rates after RT 57-75%. Both appear well-tolerated. Conclusions: In patients with an adrenal OM secondary to NSCLC, aggressive treatment should be considered. However, due to the paucity of high quality evidence, it is unclear at present whether this approach alters the natural history of the disease.

show abstract

“…Several studies have explored radiotherapy for primary tumor sites in patients with advanced lung cancer, and the results suggested that it was able to improve the local control rate, relieve the symptoms, and improve the survival rate. However, this benefit was mainly restricted to patients with good performance status and to those with metastases or single metastasis of limited volume (Nestle et al, 2000;Bezjak et al, 2002;Reinfuss et al, 2011;Hasselle et al, 2012). In addition, long radiotherapy intervals, long-term adverse effects, and the high costs confine the application of radiotherapy as well.…”

Section: Discussionmentioning

confidence: 99%

Effects of microwave ablation or its combination with whole-body chemotherapy on serum vascular endothelial growth factor levels in patients with stage IIIB/IV NSCLC

Sun¹,

Py²,

Guo³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

Hypofractionated Image-Guided Radiation Therapy for Patients with Limited Volume Metastatic Non-small Cell Lung Cancer

Abstract: HIGRT for oligometastatic NSCLC provides durable LeC and may provide long-term PFS in some patients. Future HIGRT studies should optimize patient selection and integration with systemic therapy.

Cited by 94 publications

References 24 publications

Surgical Treatment of Extrapulmonary Oligometastatic Non-small Cell Lung Cancer

Surgical Treatment of Extrapulmonary Oligometastatic Non-small Cell Lung Cancer

Adrenal Oligometastases Secondary to Non-small Cell Lung Cancer—What is the Optimal Treatment Approach?

Effects of microwave ablation or its combination with whole-body chemotherapy on serum vascular endothelial growth factor levels in patients with stage IIIB/IV NSCLC

Contact Info

Product

Resources

About